Several studies have suggested a positive association between serum lipid levels and blood pressure (BP). This study investigated this association in a large population from 12 European countries.
Data were taken from the European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice (ClinicalTrials.gov identifier: NCT00882336). Associations between BP and lipid levels in patients free from cardiovascular disease and with at least one major cardiovascular disease risk factor (N = 7641) were assessed using linear regression analyses.
Overall, 72.8 and 64.8% of patients had hypertension and dyslipidaemia, respectively; 47.0% had both conditions. Regression coefficients (95% confidence interval) for the associations of LDL cholesterol, non-HDL cholesterol, total cholesterol and apolipoprotein B levels with SBP, adjusted for age, sex and BMI, were 0.93 mmHg/mmol per l (0.54–1.31), 1.07 mmHg/mmol per l (0.73–1.40), 1.02 mmHg/mmol per l (0.69–1.35) and 4.94 mmHg/g per l (3.43–6.46), respectively. The corresponding values (95% confidence interval) for the associations with DBP were 0.96 mmHg/mmol per l (0.73–1.19), 0.95 mmHg/mmol per l (0.75–1.15), 0.87 mmHg/mmol per l (0.67–1.07) and 4.33 mmHg/g per l (3.42–5.23), respectively. Most of these associations remained significant whether patients were treated with statins or not.
Small but statistically significant associations between lipid levels and BP were observed in a large, multinational European population. Further research is warranted to assess the causality of this association and its implications on the management of patients with both hypertension and dyslipidaemia.
Supplemental Digital Content is available in the text
aDepartment of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
bDepartment of Preventive Medicine and Public Health, School of Medicine, Universidad Autónoma de Madrid/IdiPaz
cCIBER of Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
dDepartment of Public Health, Ghent University, Ghent, Belgium
eINSERM U 744, Institut Pasteur de Lille, Université Lille-Nord de France, Lille, France
fMedical Evidence and Observational Research, Global Medical Affairs, AstraZeneca Farmacéutica Spain, Madrid, Spain
gDepartments of Epidemiology and Medicine and Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
hSchool of Health and Caring Sciences, Linnaeus University, Kalmar, Sweden
iDépartement d’Épidémiologie et Recherche Clinique, Assistance Publique – Hôpitaux de Paris, Hôpital Bichat
jINSERM, CIC-EC 1425, ECEVE, UMR 1123
kDépartement d’Épidémiologie et Recherche Clinique, Centre de pharmacoépidémiologie (Cephepi), Assistance Publique – Hôpitaux de Paris, Hôpital Bichat
lUniversité Paris Diderot, Sorbonne Paris Cité, ECEVE, UMR 1123, Paris, France
mSwansea University School of Medicine, Swansea, UK
Correspondence to Professor Claudio Borghi, Department of Medical and Surgical Sciences, S. Orsola-Malpighi University Hospital, Via Albertoni 15 – Pad. 2, 40138 Bologna, Italy. Tel: +39 0512142843; fax: +39 051391320; e-mail: firstname.lastname@example.org
Abbreviations: ACE, angiotensin-converting enzyme; apo-A1, apolipoprotein A1; apo-B, apolipoprotein B; AT1, angiotensin II type 1; BP, blood pressure; CHD, coronary heart disease; CI, confidence interval; CVD, cardiovascular disease; EURIKA, European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol
Received 3 March, 2016
Revised 26 May, 2016
Accepted 13 July, 2016
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.jhypertension.com).